ASCO oncology conference: ImmunoGen (IMGN) +4.9% after it says its SAR3419 compound for...


ASCO oncology conference: ImmunoGen (IMGN) +4.9% after it says its SAR3419 compound for non-Hodgkin's lymphoma and other B-cell malignancies showed improved safety and performance in a Phase I trial that used a modified dosing schedule. The drug has been licensed to Sanofy (SNY +0.75%)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs